ADC Therapeutics (ADCT) Income towards Parent Company (2019 - 2023)
Historic Income towards Parent Company for ADC Therapeutics (ADCT) over the last 5 years, with Q3 2023 value amounting to -$47807.0.
- ADC Therapeutics' Income towards Parent Company fell 10009.45% to -$47807.0 in Q3 2023 from the same period last year, while for Dec 2023 it was -$154350.0, marking a year-over-year decrease of 10011.73%. This contributed to the annual value of -$155800.0 for FY2022, which is 3226.85% up from last year.
- Per ADC Therapeutics' latest filing, its Income towards Parent Company stood at -$47807.0 for Q3 2023, which was down 10009.45% from -$47117.0 recorded in Q2 2023.
- In the past 5 years, ADC Therapeutics' Income towards Parent Company registered a high of $126.6 million during Q2 2020, and its lowest value of -$59426.0 during Q1 2023.
- In the last 5 years, ADC Therapeutics' Income towards Parent Company had a median value of $16.7 million in 2022 and averaged $30.4 million.
- As far as peak fluctuations go, ADC Therapeutics' Income towards Parent Company surged by 54214642.8% in 2020, and later crashed by 10035.67% in 2023.
- ADC Therapeutics' Income towards Parent Company (Quarter) stood at -$35285.0 in 2019, then skyrocketed by 57710.88% to $20.3 million in 2020, then plummeted by 100.17% to -$34381.0 in 2021, then grew by 29.74% to -$24157.0 in 2022, then crashed by 97.9% to -$47807.0 in 2023.
- Its Income towards Parent Company was -$47807.0 in Q3 2023, compared to -$47117.0 in Q2 2023 and -$59426.0 in Q1 2023.